TITLE

Citalopram did not differ from placebo for treatment of depression in patients ≥ 75 years of age: COMMENTARY

AUTHOR(S)
Rochon, Paula; Lee, Philip E.
PUB. DATE
May 2005
SOURCE
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p79
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents information related to the treatment for depression in patients. Although depression in older adults is often managed with drug therapy, much of the evidence of the benefit of these therapies has been obtained from studies of younger patients. Citalopram prevented recurrent depression in older adults and a systematic review of 30 randomized controlled trials concluded that citalopram was effective for treatment of depression in elderly patients and those with comorbid conditions.
ACCESSION #
17116553

 

Related Articles

  • Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder. Hunter, Aimee; Cook, Ian; Tartter, Molly; Sharma, Simi; Disse, Gregory; Leuchter, Andrew // Psychopharmacology;Oct2015, Vol. 232 Issue 20, p3833 

    Rationale: A history of antidepressant treatment may predispose subjects toward placebo nonresponse in randomized controlled trials (RCTs) in major depressive disorder (MDD). Objective: The objective of this study is to examine self-reported prior antidepressant treatment and response in...

  • Prophylactic effect of citalopram in unipolar, recurrent depression. Hochstrasser, B.; Isaksen, P. M.; Koponen, H.; Lauritzen, L.; Mahnert, F. A.; Rouillon, F.; Wade, A. G.; Andersen, M.; Pedersen, S. F.; de Swart, J. C. G.; Nil, R. // British Journal of Psychiatry;Apr2001, Vol. 178, p304 

    Background Major depression is highly recurrent. Antidepressant maintenance treatment has proven efficacy against recurrent depression. Aims Comparison of prophylactic efficacy of citalopram versus placebo in unipolar, recurrent depression. Methods Patients 18–65 years of age with...

  • Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Leuchter, Andrew F.; Morgan, Melinda; Cook, Ian A.; Dunkin, Jennifer; Abrams, Michelle; Witte, Elise // Psychopharmacology;2004, Vol. 177 Issue 1/2, p15 

    Rationale: High placebo response rates are a confound in treatment trials for major depressive disorder (MDD). A method for prospective identification of placebo responders could enhance the efficiency of clinical trials. Objective: The objective was to identify the neurophysiological,...

  • An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials. Mi, Michael Y; Betensky, Rebecca A // Clinical Trials;Apr2013, Vol. 10 Issue 2, p207 

    No abstract available.

  • A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlfaxine Treatment in Outpatients with Major Depressive Disorder. Feiger, Alan D.; Tourian, Karen A.; Rosas, Gregory R.; Padmanabhan, S. Krishna // CNS Spectrums: The International Journal of Neuropsychiatric Med;Jan2009, Vol. 14 Issue 1, p41 

    Introduction: This research compares the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) versus placebo in treating major depressive disorder. Methods: In this randomized, double-blind study, outpatients with major depressive disorder ⩾ 18 years of age...

  • Issues in treating depression in primary care. Horn, N. R. // CME: Continuing Medical Education;Feb2013, Vol. 31 Issue 2, p46 

    The article explores the issues associated with the treatment of depression in primary care. The real world symptoms that depressed patients present are mentioned. The factors which complicate the translation of clinical trial results to clinical practice are also presented. Highlighted as well...

  • Clinical Response and Symptomatic Remission in Children Treated With Lisdexamfetamine Dimesylate for Attention-Deficit/Hyperactivity Disorder. Findling, Robert L.; Adeyi, Ben; Chen, Gary; Dirks, Bryan; Babcock, Thomas; Scheckner, Brian; Lasser, Robert; Pucci, Michael L.; Abdullah, Huda I.; McGough, James J. // CNS Spectrums: The International Journal of Neuropsychiatric Med;Sep2010, p3 

    Objective: To examine clinical response and symptomatic remission in two studies of lisdexamfetamine dimesylate (LDX) in children with attention-deficit/hyperactivity disorder (ADHD). Methods: In a 4-week, placebo-controlled, double-blind trial, children 6-12 years of age with ADHD received LDX...

  • Psicoterapia frente a farmacoterapia en depresión en atención ambulatoria. Güemes, I.; Guillen, V.; Ballesteros, J. // Actas Espanolas de Psiquiatria;sep2008, Vol. 36 Issue 5, p79 

    Depression in Europe has a prevalence rate of 3,9%. One of the main work loads in out-patient care comes from treatment of affective disorders. The objective of the present study is to compare the efficacy of psychotherapy versus drug therapy in the treatment of affective disorders. The...

  • Agomelatine: A Preliminary Review of a New Antidepressant. Zupancic, Michael; Guilleminault, Christian // CNS Drugs;2006, Vol. 20 Issue 12, p981 

    Agomelatine is a new antidepressant that is a potent agonist of melatonin receptors and an antagonist of the serotonin 5-HT2C receptor subtype. It is in late-phase trials for the treatment of major depressive disorder (MDD).Symptoms of depression significantly improved with agomelatine compared...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics